![]() ![]() ![]() “But despite the speed of response to Covid-19, some 80% of clinical trials are still delayed or closed due to a lack of participants. “The importance of clinical research has never been more clear than in the past year, as the industry stepped up to develop treatments and vaccines faster than could ever have been imagined,” said Laurent Schockmel, CEO of Antidote. Sebastien Woynar and Franck Noiret of LBO France will join the Antidote Board as a director and an observer, respectively. Through its Digital Health 2 fund, LBO France is investing $10 million, joining existing major investors Merck Global Health Innovation Fund, Smedvig Capital, and Octopus Ventures, who between them are investing $13.2 million. The funding round was led by LBO France, a private equity firm committed to supporting the growth of digital health, both in transforming health systems and accelerating medical R&D. New York, NY (June 3, 2021) - Antidote Technologies Limited (“Antidote”) today announced it has closed $23.2 million in funding to expand its digital patient engagement programs and clinical trial recruitment services. ![]() The funding, led by LBO France, will be used to enhance Antidote’s platform and accelerate new data products, connecting patients to research globally ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |